Best Telehealth Providers for Foundayo (Orforglipron) in 2026
Compare reviewed GLP-1 weight loss providers, billing commitments, and the treatments their links actually offer.
We may earn a commission through provider links. Matching affiliate offers and editorial priorities affect inclusion and suggested order in commercial guides. Scores are not clinical endorsements. Disclosure · Methodology
The Ranking
What to know before choosing
The FDA approved Foundayo (orforglipron) on April 1, 2026 for chronic weight management in eligible adults. It is an oral, once-daily GLP-1 receptor agonist that may be taken with or without food. In ATTAIN-1 (NEJM 2025), 36 mg once daily produced −11.2% mean body-weight change at week 72 by the treatment-regimen estimand; the efficacy-estimand result was −12.4%. We have not verified a provider-specific Foundayo affiliate destination, so this is a clinical guide rather than a provider ranking.
Foundayo (orforglipron) was approved by the FDA on April 1, 2026, for use with a reduced-calorie diet and increased physical activity in adults with obesity or adults with overweight and at least one weight-related comorbid condition. Its FDA label says it is taken orally once daily, with or without food.
ATTAIN-1 was a 72-week, randomised, double-blind trial of once-daily orforglipron 6 mg, 12 mg, or 36 mg versus placebo in adults with obesity without diabetes. At 36 mg, mean body-weight change at week 72 was −11.2% by the treatment-regimen estimand and −12.4% by the efficacy estimand. These are distinct analyses and neither is a direct comparison with results from trials of injectable medicines.
We have not independently verified a provider-specific Foundayo affiliate destination, current cash price, manufacturer savings offer, or insurance pathway. Readers considering a prescription should confirm the exact product, pharmacy, total cost, coverage, and follow-up plan directly with a licensed clinician or dispensing pharmacy.
Methodology
This page does not rank or recommend providers because no exact Foundayo affiliate destination has been verified. It summarises FDA-approved use and the pivotal clinical evidence only.
Orforglipron and Oral GLP-1: What the Foundayo Approval Means
FDA approved Foundayo (orforglipron) on April 1, 2026, for chronic weight management in eligible adults. It is a once-daily oral GLP-1 receptor agonist that can be taken with or without food. Here is what the FDA approval and ATTAIN-1 trial establish — and what this guide does not verify about individual telehealth providers.
What Orforglipron Is and How It Differs
Orforglipron is a small-molecule GLP-1 receptor agonist taken as a once-daily oral pill. The FDA-approved Foundayo label says it may be taken with or without food and is used with a reduced-calorie diet and increased physical activity in eligible adults.
ATTAIN-1 studied once-daily orforglipron 6 mg, 12 mg, and 36 mg versus placebo for 72 weeks in adults with obesity without diabetes. At 36 mg, mean body-weight change at week 72 was −11.2% by the treatment-regimen estimand and −12.4% by the efficacy estimand. Those analyses answer different questions and should be identified rather than combined.
Who Is a Good Candidate for Oral GLP-1
Foundayo is FDA-approved for adults with obesity or adults with overweight and at least one weight-related comorbid condition. A licensed prescriber should assess whether its labeled use, medical history, contraindications, concurrent medicines, and treatment goals make it appropriate for a particular patient.
ATTAIN-1 was not a head-to-head comparison with injectable semaglutide or tirzepatide. Separate-trial efficacy figures cannot determine which medication will be more effective or appropriate for an individual patient.
Telehealth Prescribing and Availability
This guide does not verify individual telehealth clinics that prescribe or dispense Foundayo, their prices, their affiliate destinations, or their insurance-navigation services. Those details can change and should be confirmed directly with a licensed prescriber, dispensing pharmacy, and insurer.
Before starting any online prescription pathway, confirm the exact product and dose, pharmacy, total cost, coverage requirements, contraindications, adverse-effect follow-up, and how to contact the clinical team. FDA-approved use does not establish that a particular telehealth offer is available or appropriate.
Foundayo provides an FDA-approved oral option for eligible adults, but ATTAIN-1 does not answer how it compares directly with injectable medicines or which online provider is right for a patient. Use a licensed prescriber to make an individualized treatment decision.
What the Studies Actually Show
Foundayo contains orforglipron. The figures below distinguish ATTAIN-1's treatment-regimen and efficacy estimands and use the FDA approval announcement for approved use.
| Endpoint | Finding |
|---|---|
| Mean body-weight change at 72 weeks (ATTAIN-1, treatment-regimen estimand)1 | −11.2% with orforglipron 36 mg once daily vs −2.1% with placebo in adults with obesity without diabetes. |
| Mean body-weight change at 72 weeks (ATTAIN-1, efficacy estimand)1 | −12.4% with orforglipron 36 mg once daily. This estimand assumes participants remained on assigned treatment without prohibited weight-management treatment. The efficacy and treatment-regimen estimands answer different questions and should not be treated as interchangeable figures. |
Frequently Asked Questions
What is Foundayo?
Foundayo is the brand name for orforglipron, a once-daily oral GLP-1 receptor agonist from Eli Lilly. The FDA approved it on April 1, 2026 for chronic weight management, with a reduced-calorie diet and increased physical activity, in adults with obesity or adults with overweight and at least one weight-related comorbid condition.
How is Foundayo different from Wegovy or Zepbound?
Foundayo is a once-daily pill that may be taken with or without food; Wegovy and Zepbound are injections, and Zepbound is a dual GIP/GLP-1 agonist. In the 72-week ATTAIN-1 trial, orforglipron 36 mg produced −11.2% mean body-weight change by the treatment-regimen estimand (−12.4% by the efficacy estimand). Separate-trial results should not be treated as a head-to-head efficacy comparison with Wegovy or Zepbound.
How much does Foundayo cost?
We have not independently verified a current Foundayo cash price, manufacturer savings offer, or telehealth access fee for this guide. Confirm the total prescription and dispensing cost directly with the manufacturer, pharmacy, or licensed prescriber.
Is Foundayo covered by insurance?
Coverage and prior-authorization requirements vary by plan. We have not verified a provider-specific Foundayo insurance-navigation service; contact your insurer and prescribing clinician for current coverage details.
- ATTAIN-1 — NEJM 2025 · Wharton S et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025;393:1796–1806.
RxNotebook is an editorial publication, not a medical practice. We are not affiliated with the cited studies; source material does not endorse the providers shown. This is general information, not medical advice.